Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Non Operating Income (2022 - 2025)

Historic Non Operating Income for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $1.3 million.

  • Taysha Gene Therapies' Non Operating Income rose 24518.72% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 9678.0%. This contributed to the annual value of $2.2 million for FY2024, which is 10552.3% up from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Non Operating Income is $1.3 million, which was up 24518.72% from -$237000.0 recorded in Q2 2025.
  • Taysha Gene Therapies' Non Operating Income's 5-year high stood at $64.0 million during Q4 2023, with a 5-year trough of -$100.8 million in Q3 2023.
  • In the last 4 years, Taysha Gene Therapies' Non Operating Income had a median value of -$237000.0 in 2025 and averaged -$2.6 million.
  • Data for Taysha Gene Therapies' Non Operating Income shows a peak YoY increase of 585422.66% (in 2023) and a maximum YoY decrease of 932401.87% (in 2023) over the last 5 years.
  • Taysha Gene Therapies' Non Operating Income (Quarter) stood at -$1.1 million in 2022, then soared by 5854.23% to $64.0 million in 2023, then crashed by 98.21% to $1.1 million in 2024, then increased by 12.55% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, -$237000.0 for Q2 2025, and -$108000.0 during Q1 2025.